|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives显示文摘Gastric cancer(GC)represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year.In the last decade,the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced GC and granted better survival expectations to the patients.At the same time,global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease,resulting in the identification of new specific and sensitive predictive and prognostic biomarkers and in innovative molecular classifications based on gene expression profiling.Nonetheless,several randomized studies aimed at exploring new innovative agents,such as immune checkpoint inhibitors,failed to demonstrate clinically meaningful survival advantages.Therefore,it is essential to further improve the molecular characterization of GC subgroups in order to provide researchers and medical oncologists with new tools for patients’selection and stratification in future clinical development programs and subsequent trials.The aim of the present manuscript is to provide a global overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC. | Antonio Pellino Erika Riello Floriana Nappo Stefano Brignola Sabina Murgioni Selma Ahcene Djaballah Sara Lonardi Vittorina Zagonel Massimo Rugge Fotios Loupakis Matteo Fassan | 2019 | World Journal of Gastroenterology2019，25，38： | 9 |
| 2 | Caveolin‐1 is a novel regulator of K‐RAS ‐dependent migration in colon carcinogenesis显示文摘 | Upal K. Basu Roy Rebecca S. Henkhaus Fotios Loupakis Chiara Cremolini Eugene W. Gerner Natalia A. Ignatenko | 2013 | Int J Cancer2013，，1： | 2 |
| 3 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial显示文摘 | Gianluca Masi Fotios Loupakis Lisa Salvatore Lorenzo Fornaro Chiara Cremolini Samanta Cupini Andrea Ciarlo Francesca Del Monte Enrico Cortesi Domenico Amoroso Cristina Granetto Gabriella Fontanini Elisa Sensi Cristiana Lupi Michele Andreuccetti Alfredo Fa | 2010 | Lancet Oncology2010，，9： | 2 |
| 4 | Pharma- cogenetic profiling' in patients with advanced color- ectal cancer treated with first-line FOLFOX-4 chem- otherapy显示文摘 | Ruzzo A Graziano F Loupakis F | 2007 | J ClinOncol2007，25，10： | 1 |
| 5 | Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer显示文摘 | Graziano F Ruzzo A Loupakis F | 2008 | J Clin Oncol2008，26，9： | 1 |
| 6 | Palliative treatment of unresectable metastatic colorectal cancer显示文摘 | Fornaro L Masi G Loupakis F | | 0，，01： | 1 |
| 7 | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label,phase 3 TRIBE study 显示文摘 | Cremolini C Loupakis F Antoniotti C | 2015 | Lancet Oncol2015，16，13： | 1 |
| 8 | Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis显示文摘 | Basu Roy UK Henkhaus RS Loupakis F | 2013 | Int J Cancer2013，133，1： | 1 |
| 9 | Primary tumor lo- cation as a prognostic factor in metastatic colorectal cancer显示文摘 | Loupakis F Yang D Yau L | 2015 | J Natl Cancer Inst2015，107，3： | 1 |
| 10 | Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab显示文摘 | Loupakis F Cremolini C Yang D | 2013 | PLo S One2013，8，66： | 1 |
| 11 | Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment 显示文摘 | Loupakis F Pollina L Stasi I | 2008 | J Clin Oncol2008，，： | 1 |
| 12 | PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for pa- tients with metastatic colorectal cancer显示文摘 | Loupakis F Pollina L Stasi I | 2009 | J Clin Oncol2009，27，16： | 1 |
| 13 | PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer显示文摘 | LOUPAKIS F POLLINA L STASI I | 2009 | J Clin Oncol2009，27，16： | 1 |
| 14 | High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice 显示文摘 | Santini D Loupakis F Vincenzi B | 2008 | Oncologist2008，13，： | 1 |
| 15 | Liquid biopsy:monitoring cancer-genetics in the blood显示文摘 | Crowley E Di Nicolantonio F Loupakis F | 2013 | Nat Rev Clin Oncol2013，10，8： | 1 |
| 16 | KRAS codon61,146 and BRAF mutations predict resistance to cetu-ximab plus irinotecan in KRAS codon 12 and 13 wild-typemetastatic colorectal cancer显示文摘 | Loupakis F Ruzzo A Cremolini C | 2009 | Br J Cancer2009，101，4： | 1 |
| 17 | Liquid biopsy: monitoring cancer-genetics in the blood 显示文摘 | Crowley E Di Nicolantonio F Loupakis F | 2013 | Nat Rev Clin Oncol2013，10，8： | 1 |
| 18 | First-line 5- fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer 显示文摘 | Masi G Marcucci L Loupakis F | 2006 | Ann Oncol2006，17，： | 1 |
| 19 | Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment 显示文摘 | Loupakis F Pollina L Stasi I et at | 2008 | J Clin Oncol2008，26，： | 1 |
| 20 | Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-llne treatment of metastatic colorectal cancer 显示文摘 | Masi G Vasile E Loupakis F | 2008 | Clin Colorectal Cancer2008，7，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员